EXPIRES TOMORROW: Full Transcript of Our Urgent Broadcast on India's Revival
Here is the latest financial fact sheet of AJANTA PHARMA. For more details, see the AJANTA PHARMA quarterly results and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 1.5 |
No. of shares | m | 87.95 |
% ch week | % | 0.5 |
% ch 1-mth | % | -5.3 |
% ch 12-mth | % | 22.9 |
52 week H/L | Rs | 1,883.0/1,283.1 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
AJANTA PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 779 | 1,720 | 2,098 | 1,818 | 1,422 | |
Low | Rs | 299 | 1,103 | 1,351 | 1,106 | 898 | |
Sales per share (Unadj.) | Rs | 166.1 | 195.3 | 223.4 | 239.5 | 233.5 | |
Earnings per share (Unadj.) | Rs | 34.9 | 46.8 | 57.1 | 52.8 | 44.0 | |
Diluted earnings per share | Rs | 35.2 | 47.3 | 57.6 | 53.3 | 44.0 | |
Cash flow per share (Unadj.) | Rs | 40.8 | 51.8 | 64.0 | 59.5 | 52.2 | |
Dividends per share (Unadj.) | Rs | 6.00 | 8.00 | 13.00 | 0 | 9.00 | |
Adj. dividends per share | Rs | 6.05 | 8.07 | 13.12 | 0.00 | 9.01 | |
Dividend yield (eoy) | % | 1.1 | 0.6 | 0.8 | 0 | 0.8 | |
Book value per share (Unadj.) | Rs | 94.8 | 134.2 | 176.6 | 230.0 | 255.1 | |
Adj. book value per share | Rs | 95.6 | 135.4 | 178.2 | 232.1 | 255.3 | |
Shares outstanding (eoy) | m | 88.71 | 88.77 | 88.77 | 88.77 | 88.02 | |
Bonus/Rights/Conversions | FV2 | - | - | - | BB | ||
Price / Sales ratio | x | 3.2 | 7.2 | 7.7 | 6.1 | 5.0 | |
Avg P/E ratio | x | 15.4 | 30.1 | 30.2 | 27.7 | 26.4 | |
P/CF ratio (eoy) | x | 13.2 | 27.2 | 26.9 | 24.6 | 22.2 | |
Price / Book Value ratio | x | 5.7 | 10.5 | 9.8 | 6.4 | 4.5 | |
Dividend payout | % | 17.2 | 17.1 | 22.8 | 0 | 20.5 | |
Avg Mkt Cap | Rs m | 47,797 | 125,299 | 153,062 | 129,782 | 102,081 | |
No. of employees | `000 | NA | NA | NA | 6.8 | 6.8 | |
Total wages/salary | Rs m | 2,006 | 2,566 | 2,954 | 3,765 | 4,307 | |
Avg. sales/employee | Rs Th | NM | NM | NM | 3,128.4 | 3,022.6 | |
Avg. wages/employee | Rs Th | NM | NM | NM | 554.0 | 633.4 | |
Avg. net profit/employee | Rs Th | NM | NM | NM | 689.7 | 569.1 |
AJANTA PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 14,736 | 17,340 | 19,833 | 21,258 | 20,554 | |
Other income | Rs m | 168 | 212 | 239 | 242 | 211 | |
Total revenues | Rs m | 14,904 | 17,551 | 20,071 | 21,499 | 20,765 | |
Gross profit | Rs m | 5,052 | 5,871 | 6,869 | 6,584 | 5,664 | |
Depreciation | Rs m | 516 | 444 | 612 | 596 | 721 | |
Interest | Rs m | 59 | 49 | 14 | 4 | 12 | |
Profit before tax | Rs m | 4,645 | 5,589 | 6,482 | 6,226 | 5,143 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | -85 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 1,462 | 1,433 | 1,413 | 1,539 | 1,273 | |
Profit after tax | Rs m | 3,099 | 4,156 | 5,068 | 4,686 | 3,870 | |
Gross profit margin | % | 34.3 | 33.9 | 34.6 | 31.0 | 27.6 | |
Effective tax rate | % | 31.5 | 25.6 | 21.8 | 24.7 | 24.8 | |
Net profit margin | % | 21.0 | 24.0 | 25.6 | 22.0 | 18.8 |
AJANTA PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 6,334 | 7,639 | 8,506 | 12,236 | 11,812 | |
Current liabilities | Rs m | 2,496 | 2,715 | 2,467 | 3,461 | 3,776 | |
Net working cap to sales | % | 26.0 | 28.4 | 30.5 | 41.3 | 39.1 | |
Current ratio | x | 2.5 | 2.8 | 3.4 | 3.5 | 3.1 | |
Inventory Days | Days | 39 | 43 | 39 | 60 | 77 | |
Debtors Days | Days | 64 | 78 | 59 | 79 | 82 | |
Net fixed assets | Rs m | 4,583 | 6,914 | 9,284 | 11,140 | 14,398 | |
Share capital | Rs m | 177 | 177 | 177 | 177 | 175 | |
"Free" reserves | Rs m | 8,186 | 11,732 | 15,500 | 20,237 | 22,277 | |
Net worth | Rs m | 8,411 | 11,909 | 15,677 | 20,414 | 22,452 | |
Long term debt | Rs m | 333 | 149 | 10 | 10 | 7 | |
Total assets | Rs m | 11,434 | 14,880 | 18,477 | 24,486 | 26,962 | |
Interest coverage | x | 79.5 | 115.3 | 477.6 | 1,519.4 | 444.3 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 1.3 | 1.2 | 1.1 | 0.9 | 0.8 | |
Return on assets | % | 27.6 | 28.3 | 27.5 | 19.2 | 14.4 | |
Return on equity | % | 36.8 | 34.9 | 32.3 | 23.0 | 17.2 | |
Return on capital | % | 52.8 | 46.8 | 41.4 | 30.5 | 23.0 | |
Exports to sales | % | 54.7 | 54.9 | 0 | 0 | 0 | |
Imports to sales | % | 4.4 | 6.0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 8,062 | 9,527 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 653 | 1,038 | 0 | 0 | 0 | |
Fx inflow | Rs m | 8,494 | 10,422 | 11,477 | 11,667 | 10,682 | |
Fx outflow | Rs m | 1,247 | 1,678 | 2,206 | 1,616 | 2,102 | |
Net fx | Rs m | 7,247 | 8,744 | 9,271 | 10,052 | 8,580 |
AJANTA PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 2,794 | 3,261 | 6,093 | 2,811 | 3,748 | |
From Investments | Rs m | -1,584 | -2,091 | -3,831 | -2,561 | -2,228 | |
From Financial Activity | Rs m | -1,052 | -1,173 | -2,018 | -2 | -1,475 | |
Net Cashflow | Rs m | 159 | -3 | 244 | 248 | 45 |
Share Holding
|
Company Information
|
CHM: Mannalal B. Agrawal | COMP SEC: Gaurang Shah | YEAR OF INC: 1979 | BSE CODE: 532331 | FV (Rs): 5 | DIV YIELD (%): 0.5 |
Read: AJANTA PHARMA 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: SUVEN LIFE SCIENCES PROCTER & GAMBLE HEALTH J.B.CHEMICALS VENUS REMEDIES PIRAMAL ENTERPRISES
Compare AJANTA PHARMA With: SUVEN LIFE SCIENCES PROCTER & GAMBLE HEALTH J.B.CHEMICALS VENUS REMEDIES PIRAMAL ENTERPRISES
Compare AJANTA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More